MBOT Stock Risk & Deep Value Analysis
Microbot Medical Inc
Healthcare • Medical Instruments & Supplies
DVR Score
out of 10
What You Need to Know About MBOT Stock
We analyzed Microbot Medical Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MBOT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
MBOT Risk Analysis & Red Flags
What Could Go Wrong
The primary risk facing Microbot Medical Inc. is its rapidly dwindling cash reserves, estimated at 5.5-6 months as of mid-March 2026, combined with slower-than-expected commercial adoption of the LIBERTY system. This could necessitate a highly dilutive financing round or threaten ongoing operations before LIBERTY revenue can sufficiently offset the company's estimated $3M-$4M quarterly cash burn (based on historical burn rates for early-stage medical device companies).
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Stock declined 14.8% after announcing first LIBERTY revenue, potentially indicating market disappointment or underlying concerns not publicly disclosed.
- ⚠
Investor conference call scheduled to address 'misstatements in a recent third-party article' (May 18, 2026), suggesting potential for negative sentiment or misinformation impacting valuation.
- ⚠
Lack of transparency regarding specific Q1 2026 LIBERTY revenue figures and current cash position in provided research, which is crucial for assessing financial runway.
Upcoming Risk Events
- 📅
Q2 2026 earnings report shows flat or declining LIBERTY revenue, or significant increase in cash burn without offsetting revenue (estimated late July/early Aug 2026).
- 📅
Failure to secure additional financing (equity or debt) by Q4 2026, leading to severe liquidity issues and operational disruption.
When to Reconsider
- 🚪
Exit if quarterly LIBERTY revenue fails to exceed $1.5M by Q4 2026, indicating inadequate commercial traction.
- 🚪
Sell if the company announces a financing round that results in >25% dilution from current shares outstanding without a corresponding substantial increase in strategic value or revenue guidance.
Unlock MBOT Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Microbot Medical Inc (MBOT) Do?
Market Cap
$136.34M
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
20
Microbot Medical Inc. is a medical device company that focuses on transforming endovascular procedures through advanced robotic technology. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts
Visit Microbot Medical Inc WebsiteInvestment Thesis
If Microbot Medical successfully scales the commercialization of its FDA-cleared LIBERTY system, expanding its installed base beyond initial sites and securing additional international regulatory approvals (e.g., EU), it could achieve an annualized revenue run-rate of $50M-$70M within the next 2-3 years. This could re-rate its valuation to 8-12x Price/Sales for a market capitalization of $400M-$840M, which is bullish given its current $0.14B valuation that doesn't fully price in successful commercial execution and future market leadership.
Is MBOT Stock Undervalued?
Unlock the full AI analysis for MBOT
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
MBOT Price Targets & Strategy
12-Month Target
$4.50
Bull Case
$8.00
Bear Case
$1.00
Valuation Basis
Based on projected FY2027 annual revenue of $15M-$20M and an aggressive 15-20x Price/Sales multiple for a high-growth, disruptive medical device company achieving commercial traction.
Entry Strategy
Dollar-cost average between $1.80-$2.20, near recent support levels and acknowledging current volatility.
Exit Strategy
Take 50% profit at $4.50, with a stop-loss order at $1.50 to manage downside risk if commercialization stalls or financing becomes overly dilutive.
Portfolio Allocation
5% for aggressive risk tolerance.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is MBOT Financially Healthy?
Valuation
P/E Ratio
2.03
Forward P/E
-6.06
EV/EBITDA
-10.84
Price/Book
1.39
Price/Sales
154.29
Profitability
Gross Margin
1.90%
Operating Margin
-4114.29%
Net Margin
-3496.19%
Return on Equity
-21.84%
EPS
$-0.28
Balance Sheet
Current Ratio
23.33
Quick Ratio
23.04
Cash & Equivalents
$72.50M
Cash Flow
Operating Cash Flow
-$5.10M
Free Cash Flow
-$5.10M
EBITDA
-$3.80M
Other
Beta (Volatility)
1.02
Does MBOT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat will persist if Microbot continues to innovate and secure further intellectual property, establishing LIBERTY as a standard of care. However, it faces risks from larger, well-funded competitors who could replicate or acquire similar technologies.
Moat Erosion Risks
- •Rapid advancements by competitors in micro-robotics or alternative minimally invasive techniques, potentially eroding technological lead.
- •Slow adoption by medical institutions due to high upfront costs, extensive training requirements, or lack of compelling long-term clinical data to justify investment.
MBOT Competitive Moat Analysis
Sign up to see competitive advantages
MBOT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. While commercial launch is positive, the stock's negative reaction to first revenue and the need for an investor call suggest mixed sentiment and investor caution.
Institutional Sentiment
Neutral. No specific analyst upgrades/downgrades or institutional buying data provided in the research. The early stage of commercialization likely keeps institutional interest cautious.
Insider Activity (Form 4)
No specific Form 4 insider transactions with names, titles, share counts, prices, or dates were provided in the research for the last 90 days. Therefore, no confirmed insider activity can be reported.
Options Flow
Normal options activity. No specific unusual put/call ratio or large block trades were indicated in the provided research.
Earnings Intelligence
Next Earnings
Estimated late July/early August 2026 (for Q2 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Unpredictable due to early stage and only recently reporting first revenue. The stock notably fell 14.8% after the Q1 2026 revenue announcement, indicating investor sensitivity to initial commercialization results.
Key Metrics to Watch
Competitive Position
Top Competitor
Could not be definitively identified from the provided research, but likely larger robotic surgery or interventional device companies (e.g., Intuitive Surgical, Medtronic, Boston Scientific) which, while not direct micro-robotics competitors, possess superior resources and market presence.
Market Share Trend
Gaining from a base of near zero as it begins commercialization in a niche but growing market.
Valuation vs Peers
Not meaningful for P/E given pre-profit status. On a Price/Sales basis (if revenue becomes substantial), it would likely trade at a premium to established, slower-growth medical device companies due to its high growth potential, but at a discount to other pure-play, de-risked robotic surgery innovators until commercial scale is proven.
Competitive Advantages
- •Proprietary micro-robotic technology and intellectual property for endovascular procedures.
- •FDA-cleared LIBERTY system, a significant regulatory hurdle passed, and subsequent Israeli approval.
- •Potential for first-mover advantage in this specialized micro-robotic endovascular segment.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive MBOT Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (estimated late July/early Aug 2026): Strong sequential growth in LIBERTY revenue (e.g., >$0.5M) and positive guidance for Q3.
- •Announcement of first major hospital system installation(s) for LIBERTY in a new U.S. region (Q3 2026): Indicates expanding commercial footprint beyond initial sites.
Medium-Term (6-18 months)
- •Receipt of CE Mark approval for LIBERTY in the EU (estimated Q4 2026-Q1 2027): Opens up a significant new market for commercialization.
- •Presentation of initial clinical data or case studies from LIBERTY users at a major medical conference (e.g., TCT, CIRSE, estimated Q1-Q2 2027): Demonstrates real-world efficacy and safety, driving physician adoption.
Long-Term (18+ months)
- •Expansion of LIBERTY's indications for use to additional endovascular procedures (e.g., neurovascular, peripheral vascular, estimated by 2028): Broadens total addressable market and recurring revenue streams.
- •Strategic partnership or acquisition by a large medical device company (estimated by 2029): Provides capital, distribution, and validation, potentially valuing MBOT at 5x-10x current market cap.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for MBOT?
- ✓
Quarterly LIBERTY revenue growth: targeting sequential growth exceeding 40% for the next 4-6 quarters to demonstrate adoption acceleration.
- ✓
Cash and cash equivalents: must see stabilization or growth in the balance sheet, or announcement of non-dilutive financing, to alleviate liquidity concerns.
- ✓
Number of LIBERTY system installations: an increase to 10+ active sites by Q4 2026 would signal successful market penetration.
Bull Case Analysis
Sign up free to see the bull case
Competing with MBOT
See how Microbot Medical Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Microbot Medical Inc MBOT | $136.3M | 7.2 | 2.0 | $105,000 | -3496.2% | — | |
Intuitive Surgical Inc ISRG | $166.6B | 3.0 | 58.4 | $10.1B | 28.4% | 20.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Microbot Medical Inc Makes Money
Microbot Medical Inc. is a pre-profitability medical device company focused on developing and commercializing disposable micro-robotic systems for minimally invasive endovascular surgical procedures. Its flagship product, the FDA-cleared LIBERTY system, aims to provide physicians with enhanced precision and control, potentially improving outcomes for complex procedures. The company primarily intends to generate revenue through the sale of these robotic systems to hospitals and surgical centers, along with recurring revenue from sales of specialized disposable components used in each procedure, operating on a 'razor-and-blade' model.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Microbot Medical Inc (MBOT)?
As of June 1, 2026, Microbot Medical Inc has a DVR Score of 7.2 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Microbot Medical Inc?
Microbot Medical Inc's market capitalization is approximately $136.3M. The company operates in the Healthcare sector within the Medical Instruments & Supplies industry.
What ticker symbol does Microbot Medical Inc use?
MBOT is the ticker symbol for Microbot Medical Inc. The company trades on the NCM.
What is the risk level for MBOT stock?
Our analysis rates Microbot Medical Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of MBOT?
Microbot Medical Inc currently has a price-to-earnings (P/E) ratio of 2.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is MBOT stock profitable?
Microbot Medical Inc has a profit margin of -3496.2%. The company is currently unprofitable.
How often is the MBOT DVR analysis updated?
Our AI-powered analysis of Microbot Medical Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 1, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for MBOT (Microbot Medical Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.